{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:23:25Z","timestamp":1791890605571,"version":"4.3.4"},"reference-count":85,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","award":["CNPq 311143\/2021-0"],"award-info":[{"award-number":["CNPq 311143\/2021-0"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","award":["440013\/2022-4"],"award-info":[{"award-number":["440013\/2022-4"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","award":["440006\/2022-8"],"award-info":[{"award-number":["440006\/2022-8"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","award":["FAPERJ\u2013CNE E-26\/200.861\/2021"],"award-info":[{"award-number":["FAPERJ\u2013CNE E-26\/200.861\/2021"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","award":["001"],"award-info":[{"award-number":["001"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Research Support of the State of Rio de Janeiro","award":["CNPq 311143\/2021-0"],"award-info":[{"award-number":["CNPq 311143\/2021-0"]}]},{"name":"Research Support of the State of Rio de Janeiro","award":["440013\/2022-4"],"award-info":[{"award-number":["440013\/2022-4"]}]},{"name":"Research Support of the State of Rio de Janeiro","award":["440006\/2022-8"],"award-info":[{"award-number":["440006\/2022-8"]}]},{"name":"Research Support of the State of Rio de Janeiro","award":["FAPERJ\u2013CNE E-26\/200.861\/2021"],"award-info":[{"award-number":["FAPERJ\u2013CNE E-26\/200.861\/2021"]}]},{"name":"Research Support of the State of Rio de Janeiro","award":["001"],"award-info":[{"award-number":["001"]}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior\u2014Brasil (CAPES)","doi-asserted-by":"publisher","award":["CNPq 311143\/2021-0"],"award-info":[{"award-number":["CNPq 311143\/2021-0"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior\u2014Brasil (CAPES)","doi-asserted-by":"publisher","award":["440013\/2022-4"],"award-info":[{"award-number":["440013\/2022-4"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior\u2014Brasil (CAPES)","doi-asserted-by":"publisher","award":["440006\/2022-8"],"award-info":[{"award-number":["440006\/2022-8"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior\u2014Brasil (CAPES)","doi-asserted-by":"publisher","award":["FAPERJ\u2013CNE E-26\/200.861\/2021"],"award-info":[{"award-number":["FAPERJ\u2013CNE E-26\/200.861\/2021"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior\u2014Brasil (CAPES)","doi-asserted-by":"publisher","award":["001"],"award-info":[{"award-number":["001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>The primary treatment for chronic myeloid leukemia (CML) involves first- and second-generation tyrosine kinase inhibitors (TKIs), such as imatinib, nilotinib, bosutinib, and dasatinib. However, these medications are ineffective against mutations in the kinase domain of the ABL1 protein, particularly in the protein with the T315I mutation. To address this, ponatinib (PNT), a third-generation inhibitor, was developed. Despite its efficacy in treating the BCR-ABL1T315I mutation, the use of PNT was briefly suspended in 2013 due to serious adverse effects but was subsequently reintroduced to the market. During the drug discovery and development process, it is rare to consolidate all information into a single article, as is the case with ponatinib. This review aims to compile and chronologically organize the research on the discovery of ponatinib using medicinal chemistry tools and computational methods. It includes in silico calculations, such as the octanol\/water partition coefficient (cLogP) via SwissAdme, and 2D maps of intermolecular interactions through molecular docking. This approach enhances understanding for both specialists and those interested in medicinal chemistry and pharmacology, while also contextualizing future directions for further optimizations of ponatinib, facilitating the development of new analogs of this crucial inhibitor for the treatment of CML and Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL).<\/jats:p>","DOI":"10.3390\/ph17101361","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T04:02:58Z","timestamp":1728878578000},"page":"1361","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Ponatinib: A Review of the History of Medicinal Chemistry behind Its Development"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2252-2232","authenticated-orcid":false,"given":"Mayara","family":"Nascimento","sequence":"first","affiliation":[{"name":"Programa de P\u00f3s-Gradua\u00e7\u00e3o em Farmacologia e Qu\u00edmica Medicinal do Instituto de Ci\u00eancias Biom\u00e9dicas\u2013ICB-UFRJ, Centro de Ci\u00eancias da Sa\u00fade-CCS, Bloco J, Ilha do Fund\u00e3o, Rio de Janeiro 21941-902, RJ, Brazil"},{"name":"Departamento de S\u00edntese de F\u00e1rmacos, Instituto de Tecnologia em F\u00e1rmacos, Farmanguinhos\u2013Fiocruz, Manguinhos, Rio de Janeiro 21041-250, RJ, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefany","family":"Moura","sequence":"additional","affiliation":[{"name":"Programa de P\u00f3s-Gradua\u00e7\u00e3o em Farmacologia e Qu\u00edmica Medicinal do Instituto de Ci\u00eancias Biom\u00e9dicas\u2013ICB-UFRJ, Centro de Ci\u00eancias da Sa\u00fade-CCS, Bloco J, Ilha do Fund\u00e3o, Rio de Janeiro 21941-902, RJ, Brazil"},{"name":"Departamento de S\u00edntese de F\u00e1rmacos, Instituto de Tecnologia em F\u00e1rmacos, Farmanguinhos\u2013Fiocruz, Manguinhos, Rio de Janeiro 21041-250, RJ, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Parra","sequence":"additional","affiliation":[{"name":"Programa de P\u00f3s-Gradua\u00e7\u00e3o Acad\u00eamico em Pesquisa Translacional em F\u00e1rmacos e Medicamentos\u2013Farmanguinhos, Funda\u00e7\u00e3o Oswaldo Cruz, Rio de Janeiro 21041-250, RJ, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeska","family":"Vasconcellos","sequence":"additional","affiliation":[{"name":"Departamento de S\u00edntese de F\u00e1rmacos, Instituto de Tecnologia em F\u00e1rmacos, Farmanguinhos\u2013Fiocruz, Manguinhos, Rio de Janeiro 21041-250, RJ, Brazil"},{"name":"Programa de P\u00f3s-Gradua\u00e7\u00e3o Acad\u00eamico em Pesquisa Translacional em F\u00e1rmacos e Medicamentos\u2013Farmanguinhos, Funda\u00e7\u00e3o Oswaldo Cruz, Rio de Janeiro 21041-250, RJ, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Costa","sequence":"additional","affiliation":[{"name":"Departamento de S\u00edntese de F\u00e1rmacos, Instituto de Tecnologia em F\u00e1rmacos, Farmanguinhos\u2013Fiocruz, Manguinhos, Rio de Janeiro 21041-250, RJ, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora","family":"Leite","sequence":"additional","affiliation":[{"name":"Departamento de S\u00edntese de F\u00e1rmacos, Instituto de Tecnologia em F\u00e1rmacos, Farmanguinhos\u2013Fiocruz, Manguinhos, Rio de Janeiro 21041-250, RJ, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7919-3252","authenticated-orcid":false,"given":"Maria","family":"Dias","sequence":"additional","affiliation":[{"name":"Departamento de S\u00edntese de F\u00e1rmacos, Instituto de Tecnologia em F\u00e1rmacos, Farmanguinhos\u2013Fiocruz, Manguinhos, Rio de Janeiro 21041-250, RJ, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5881-9519","authenticated-orcid":false,"given":"T\u00e1cio Vin\u00edcio Amorim","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Departamento de S\u00edntese de F\u00e1rmacos, Instituto de Tecnologia em F\u00e1rmacos, Farmanguinhos\u2013Fiocruz, Manguinhos, Rio de Janeiro 21041-250, RJ, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Hoelz","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio Computacional de Qu\u00edmica Medicinal\u2014LCQM, Instituto Federal do Rio de Janeiro\u2014IFRJ, Campus Pinheiral, Pinheiral 27197-000, RJ, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7850-3888","authenticated-orcid":false,"given":"Luiz","family":"Pimentel","sequence":"additional","affiliation":[{"name":"Departamento de S\u00edntese de F\u00e1rmacos, Instituto de Tecnologia em F\u00e1rmacos, Farmanguinhos\u2013Fiocruz, Manguinhos, Rio de Janeiro 21041-250, RJ, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Bastos","sequence":"additional","affiliation":[{"name":"Departamento de S\u00edntese de F\u00e1rmacos, Instituto de Tecnologia em F\u00e1rmacos, Farmanguinhos\u2013Fiocruz, Manguinhos, Rio de Janeiro 21041-250, RJ, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0146-2218","authenticated-orcid":false,"given":"Nubia","family":"Boechat","sequence":"additional","affiliation":[{"name":"Departamento de S\u00edntese de F\u00e1rmacos, Instituto de Tecnologia em F\u00e1rmacos, Farmanguinhos\u2013Fiocruz, Manguinhos, Rio de Janeiro 21041-250, RJ, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,11]]},"reference":[{"key":"ref_1","first-page":"1497","article-title":"A Minute Chromosome in Human Chronic Granulocytic Leukemia","volume":"132","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","article-title":"Philadelphia Chromosomal Breakpoints Are Clustered within a Limited Region, Bcr, on Chromosome 22","volume":"36","author":"Groffen","year":"1984","journal-title":"Cell"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine Kinase Activity and Transformation Potency of Bcr-Abl Oncogene Products","volume":"247","author":"Lugo","year":"1990","journal-title":"Science"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12943-018-0801-5","article-title":"Advances in studies of tyrosine kinase inhibitors and their acquired resistance","volume":"17","author":"Jiao","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13045-021-01055-9","article-title":"Third-Line Therapy for Chronic Myeloid Leukemia: Current Status and Future Directions","volume":"14","author":"Cortes","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/MOH.0000000000000403","article-title":"Resistance in Chronic Myeloid Leukemia: Definitions and Novel Therapeutic Agents","volume":"25","author":"Talati","year":"2018","journal-title":"Curr. Opin. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL Independence and LYN Kinase Overexpression in Chronic Myelogenous Leukemia Cells Selected for Resistance to STI571","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib Induces Durable Hematologic and Cytogenetic Responses in Patients with Accelerated Phase Chronic Myeloid Leukemia: Results of a Phase 2 Study","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ddtec.2014.03.003","article-title":"Current Aspects in Resistance against Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia","volume":"11","author":"Balabanov","year":"2014","journal-title":"Drug Discov. Today Technol."},{"key":"ref_12","first-page":"243","article-title":"Resistant Mutations in CML and Ph+ALL-Role of Ponatinib","volume":"8","author":"Miller","year":"2014","journal-title":"Biol. Targets Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.21577\/1984-6835.20180088","article-title":"Structural Characteristics of Protein Kinases and Their Inhibitors in Clinical Use","volume":"10","author":"Pauli","year":"2018","journal-title":"Rev. Virtual Quim."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s11010-022-04376-6","article-title":"Transport and Metabolism of Tyrosine Kinase Inhibitors Associated with Chronic Myeloid Leukemia Therapy: A Review","volume":"477","author":"Kumar","year":"2022","journal-title":"Mol. Cell Biochem."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Cheng, S., Jin, P., Li, H., Pei, D., and Shu, X. (2021). Evaluation of CML TKI Induced Cardiovascular Toxicity and Development of Potential Rescue Strategies in a Zebrafish Model. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.740529"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase","volume":"27","author":"Hughes","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1021\/jm100395q","article-title":"Discovery of 3-[2-(Imidazo [1,2-b]Pyridazin-3-Yl)Ethynyl]-4-Methyl-N-{4-[(4-Methylpiperazin-1-Yl)Methyl]-3-(Trifluoromethyl)Phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant","volume":"53","author":"Huang","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/j.clml.2018.05.002","article-title":"Real-Life Experience with Ponatinib in Chronic Myeloid Leukemia: A Multicenter Observational Study","volume":"18","author":"Raanani","year":"2018","journal-title":"Cl. Lymph. Myelom. Leuk."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Qian, H., Gang, D., He, X., and Jiang, S. (2022). A Review of the Therapeutic Role of the New Third-Generation TKI Olverembatinib in Chronic Myeloid Leukemia. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1036437"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1002\/ajh.27355","article-title":"Ponatinib-review of historical development, current status, and future research","volume":"99","author":"Kantarjian","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/164_2017_81","article-title":"Mechanisms of resistance to targeted therapies in chronic myeloid leukemia","volume":"249","author":"Lussana","year":"2018","journal-title":"Mech. Drug Resist. Cancer Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2147\/OTT.S189391","article-title":"Ponatinib: A Novel Multi-Tyrosine Kinase Inhibitor against Human Malignancies","volume":"12","author":"Tan","year":"2019","journal-title":"Oncotargets Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1021\/jm900166t","article-title":"9-(Arenethenyl)Purines as Dual Src\/Abl Kinase Inhibitors Targeting the Inactive Conformation: Design, Synthesis, and Biological Evaluation","volume":"52","author":"Huang","year":"2009","journal-title":"J. Med. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"9809","DOI":"10.1158\/0008-5472.CAN-08-1008","article-title":"Evidence That Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression","volume":"68","author":"Mahon","year":"2008","journal-title":"Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/1078-0432.CCR-06-2147","article-title":"Important Therapeutic Targets in Chronic Myelogenous Leukemia","volume":"13","author":"Kantarjian","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2174\/138955707779802598","article-title":"Last Findings on Dual Inhibitors of Abl and Src Tyrosine-Kinases","volume":"7","author":"Schenone","year":"2007","journal-title":"Mini-Rev. Med. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1038\/sj.leu.2403950","article-title":"Dual Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia","volume":"19","author":"Martinelli","year":"2005","journal-title":"Leukemia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/ng1343","article-title":"Requirement of Src Kinases Lyn, Hck and Fgr for BCR-ABL1-Induced B-Lymphoblastic Leukemia but Not Chronic Myeloid Leukemia","volume":"36","author":"Hu","year":"2004","journal-title":"Nat. Genet."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-Chloro-6-Methyl-Phenyl)-2-(6-(4-(2-Hydroxyethyl)-Piperazin-1-Yl)-2-Methylpyrimidin-4-Ylamino)Thiazole-5-Carboxamide (BMS-354825), a Dual Src\/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib Efficacy and Safety in Philadelphia Chromosome\u2013Positive Leukemia: Final 5-Year Results of the Phase 2 PACE Trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1158\/0008-5472.CAN-21-3652","article-title":"Reengineering Ponatinib to Minimize Cardiovascular Toxicity","volume":"82","author":"Hnatiuk","year":"2022","journal-title":"Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/ajh.26642","article-title":"Chronic Myeloid Leukemia: 2022 Update on Diagnosis, Therapy, and Monitoring","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ijcard.2020.05.077","article-title":"Cardiotoxicity of the BCR-ABL1 Tyrosine Kinase Inhibitors: Emphasis on Ponatinib","volume":"316","author":"Singh","year":"2020","journal-title":"Int. J. Cardiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1021\/acs.molpharmaceut.7b00257","article-title":"Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP\/ABCB1) and Breast Cancer Resistance Protein (BCRP\/ABCG2)","volume":"14","author":"Kort","year":"2017","journal-title":"Mol. Pharmaceut."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/jamaoncol.2015.5932","article-title":"Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival: A Systematic Review and Meta-Analysis","volume":"2","author":"Douxfils","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_36","unstructured":"(2024, June 28). Iclusig (Ponatinib) [Prescribing Information]. Available online: https:\/\/www.iclusig.com\/sites\/default\/files\/2023-02\/iclusig-prescribing-information.pdf."},{"key":"ref_37","first-page":"188949","article-title":"Ponatinib: An update on its drug targets, therapeutic potential and safety","volume":"1878","author":"Gao","year":"2023","journal-title":"BBA\u2013Rev. Cancer"},{"key":"ref_38","first-page":"612","article-title":"Targeted Therapies: A Life Saving Approach for Cancer","volume":"5","author":"Mercy","year":"2016","journal-title":"World J. Pharm. Pharm. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Li, J., Gong, C., Zhou, H., Liu, J., Xia, X., Ha, W., Jiang, Y., Liu, Q., and Xiong, H. (2024). Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25105489"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/10409238.2018.1495173","article-title":"The Src Module: An Ancient Scaffold in the Evolution of Cytoplasmic Tyrosine Kinases","volume":"53","author":"Shah","year":"2018","journal-title":"Crit. Rev. Biochem. Mol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"9624","DOI":"10.1158\/0008-5472.CAN-08-1131","article-title":"Effects of Dasatinib on Src Kinase Activity and Downstream Intracellular Signaling in Primitive Chronic Myelogenous Leukemia Hematopoietic Cells","volume":"68","author":"Konig","year":"2008","journal-title":"Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"9244","DOI":"10.1073\/pnas.0600001103","article-title":"Activity of Dual SRC-ABL Inhibitors Highlights the Role of BCR\/ABL Kinase Dynamics in Drug Resistance","volume":"103","author":"Azam","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1517\/13543784.2010.499898","article-title":"Novel Dual Src\/Abl Inhibitors for Hematologic and Solid Malignancies","volume":"19","author":"Schenone","year":"2010","journal-title":"Expert Opin. Inv. Drug"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1126\/science.1095920","article-title":"Protein Kinase Inhibitors: Insights into Drug Design from Structure","volume":"303","author":"Noble","year":"2004","journal-title":"Science"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1002\/j.1460-2075.1994.tb06897.x","article-title":"Identification of Src, Fyn, Lyn, PI3K and Abl SH3 Domain Ligands Using Phage Display Libraries","volume":"13","author":"Rickles","year":"1994","journal-title":"EMBO J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.1128\/MCB.15.10.5627","article-title":"Structure-Function Analysis of SH3 Domains: SH3 Binding Specificity Altered by Single Amino Acid Substitutions","volume":"15","author":"Weng","year":"1995","journal-title":"Mol. Cel. Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1182\/blood-2004-05-1851","article-title":"Inhibition of Wild-Type and Mutant Bcr-Abl by AP23464, a Potent ATP-Based Oncogenic Protein Kinase Inhibitor: Implications for CML","volume":"104","author":"Pollock","year":"2004","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood-2004-12-4771","article-title":"In Vitro and in Vivo Activity of ATP-Based Kinase Inhibitors AP23464 and AP23848 against Activation-Loop Mutants of Kit","volume":"106","author":"Corbin","year":"2005","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1016\/j.bmcl.2008.06.042","article-title":"Novel N9-Arenethenyl Purines as Potent Dual Src\/Abl Tyrosine Kinase Inhibitors","volume":"18","author":"Wang","year":"2008","journal-title":"Bioorg. Med. Chem. Let."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1747-0285.2009.00905.x","article-title":"Structural Analysis of DFG-in and DFG-out Dual Src-Abl Inhibitors Sharing a Common Vinyl Purine Template","volume":"75","author":"Zhou","year":"2010","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and Resistance to BCR-ABL1-Targeted Therapies","volume":"37","author":"Braun","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"32214","DOI":"10.1074\/jbc.M111525200","article-title":"Analysis of the Structural Basis of Specificity of Inhibition of the Abl Kinase by STI571","volume":"277","author":"Corbin","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1747-0285.2005.00316.x","article-title":"Structural Basis of Src Tyrosine Kinase Inhibition with a New Class of Potent and Selective Trisubstituted Purine-based Compounds","volume":"67","author":"Dalgarno","year":"2006","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Lima, L.M., Da Silva, T.F., Da Silva Monteiro, C.E., Aparecida-Silva, C., Bispo J\u00fanior, W., De Queiroz, A.C., Alexandre-Moreira, M.S., Zapata-Sudo, G., and Barreiro, E.J. (2021). Design and Synthesis in Silico Drug-like Prediction and Pharmacological Evaluation of Cyclopolymethylenic Homologous of LASSBio-1514. Molecules, 26.","DOI":"10.3390\/molecules26164828"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Daina, A., Michielin, O., and Zoete, V. (2017). SwissADME: A Free Web Tool to Evaluate Pharmacokinetics, Drug-Likeness and Medicinal Chemistry Friendliness of Small Molecules. Sci. Rep., 7, Available online: http:\/\/www.swissadme.ch\/index.php.","DOI":"10.1038\/srep42717"},{"key":"ref_56","unstructured":"Noronha, G., Cao, J., Zeng, B., Mak, C., McPherson, A., Renick, J., Pathak, V.P., Chow, C., Palanki, M., and Soll, R.M. (2007). Thiazole Inhibitors Targeting Resistant Kinase Mutations. (U.S. Patent 11\/591,252)."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1021\/jm9002928","article-title":"Hybrid Compound Design to Overcome the Gatekeeper T338M Mutation in cSrc","volume":"52","author":"Getlik","year":"2009","journal-title":"J. Med. Chem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain Elucidates Its Inhibitory Activity against Imatinib-Resistant ABL Mutants","volume":"66","author":"Tokarski","year":"2006","journal-title":"Cancer Res."},{"key":"ref_59","unstructured":"Barreiro, E.J., and Fraga, C.A.M. (2014). Qu\u00edmica Medicinal: As Bases Moleculares da A\u00e7\u00e3o dos F\u00e1rmacos, Artmed. [3rd ed.]."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1021\/cb400663k","article-title":"Conformation-Selective Inhibitors Reveal Differences in the Activation and Phosphate-Binding Loops of the Tyrosine Kinases Abl and Src","volume":"8","author":"Hari","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"ref_61","unstructured":"Wermuth, C.G., Aldous, D.J., Raboisson, P., and Rognan, D. (2015). The Practice of Medicinal Chemistry, Elsevier Academic Press. [4th ed.]."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-018-0624-2","article-title":"Past, Present, and Future of Bcr-Abl Inhibitors: From Chemical Development to Clinical Efficacy","volume":"11","author":"Rossari","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nchembio799","article-title":"Rational Design of Inhibitors That Bind to Inactive Kinase Conformations","volume":"2","author":"Liu","year":"2006","journal-title":"Nat. Chem. Biol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.chembiol.2006.05.015","article-title":"A General Strategy for Creating \u201cInactive-Conformation\u201d Abl Inhibitors","volume":"13","author":"Okram","year":"2006","journal-title":"Chem. Biol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1021\/jm050540c","article-title":"Novel Procedure for Modeling Ligand\/Receptor Induced Fit Effects","volume":"49","author":"Sherman","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.drup.2009.04.001","article-title":"FLT3 Inhibition and Mechanisms of Drug Resistance in Mutant FLT3-Positive AML","volume":"12","author":"Weisberg","year":"2009","journal-title":"Drug Resist. Updates"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1039\/a827163z","article-title":"Non-Conventional Hydrogen Bonds","volume":"27","author":"Alkorta","year":"1998","journal-title":"Chem. Soc. Rev."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1124\/dmd.108.022376","article-title":"The Molecular Basis of CYP2D6-Mediated N-Dealkylation: Balance between Metabolic Clearance Routes and Enzyme Inhibition","volume":"36","author":"Bonn","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1021\/ml200246f","article-title":"Ligand-Based Site of Metabolism Prediction for Cytochrome P450 2D6","volume":"3","author":"Rydberg","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.chembiol.2010.12.013","article-title":"Discovery and Characterization of a Cell-Permeable, Small-Molecule c-Abl Kinase Activator That Binds to the Myristoyl Binding Site","volume":"18","author":"Yang","year":"2011","journal-title":"Chem. Biol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1200\/GO.21.00058","article-title":"Spectrum of BCR-ABL Mutations and Treatment Outcomes in Ethiopian Imatinib-Resistant Patients with Chronic Myeloid Leukemia","volume":"7","author":"Tadesse","year":"2021","journal-title":"JCO Glob. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-Term Outcomes with Frontline Nilotinib versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: ENESTnd 10-Year Analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1182\/blood.V106.11.3365.3365","article-title":"Molecular Interactions between the Highly Selective Pan-Bcr-Abl Inhibitor, AMN107, and the Tyrosine Kinase Domain of Abl","volume":"106","author":"Manley","year":"2005","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a Selective Inhibitor of Native and Mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.drudis.2006.02.006","article-title":"Similarity in Drugs: Reflections on Analogue Design","volume":"11","author":"Wermuth","year":"2006","journal-title":"Drug Discov. Today"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.gde.2005.11.002","article-title":"Targeted CML Therapy: Controlling Drug Resistance, Seeking Cure","volume":"16","author":"Corbin","year":"2006","journal-title":"Curr. Opin. Genet. Dev."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance","volume":"16","author":"Shakespeare","year":"2009","journal-title":"Cancer Cell"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2174\/1568009617666171002142659","article-title":"Ponatinib: A Review of Efficacy and Safety","volume":"18","author":"Massaro","year":"2018","journal-title":"Curr. Cancer Drug Tar."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1158\/1078-0432.CCR-08-0117","article-title":"Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia","volume":"14","author":"Cortes","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e494","DOI":"10.3324\/haematol.2015.132845","article-title":"Phase II Trial of Ponatinib in Patients with Chronic Myeloid Leukemia Resistant to One Previous Tyrosine Kinase Inhibitor","volume":"100","author":"Sanford","year":"2015","journal-title":"Haematologica"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1747-0285.2010.01054.x","article-title":"Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance","volume":"77","author":"Zhou","year":"2011","journal-title":"Chem. Biol. Drug. Des."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/35030148","article-title":"A Chemical Switch for Inhibitor-Sensitive Alleles of Any Protein Kinase","volume":"407","author":"Bishop","year":"2000","journal-title":"Nature"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/leu.2016.353","article-title":"Identification and Characterization of Activating ABL1 1b Kinase Mutations: Impact on Sensitivity to ATP-Competitive and Allosteric ABL1 Inhibitors","volume":"31","author":"Lee","year":"2017","journal-title":"Leukemia"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"eabc2754","DOI":"10.1126\/science.abc2754","article-title":"Conformational States Dynamically Populated by a Kinase Determine Its Function","volume":"370","author":"Xie","year":"2020","journal-title":"Science"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/s41467-023-36956-5","article-title":"Structural Mechanism of a Drug-Binding Process Involving a Large Conformational Change of the Protein Target","volume":"14","author":"Ayaz","year":"2023","journal-title":"Nat. Commun."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/10\/1361\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:11:48Z","timestamp":1760112708000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/10\/1361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,11]]},"references-count":85,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["ph17101361"],"URL":"https:\/\/doi.org\/10.3390\/ph17101361","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,11]]}}}